Overview

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.
Treatments:
Gemcitabine